Table 4

Baseline and 3-month disease states and response rates of the second TNFi according to reason for switching

Baseline3 Months
IR switchers (n=30)AE switchers (n=44)p Value*IR switchers (n=23)AE switchers (n=39)p Value
BASDAI 50 (n (%))4 (21.1)9 (33.3)0.36
ASAS20 (n (%))6 (31.6)12 (46.2)0.32
ASAS40 (n (%))6 (31.6)8 (30.8)0.95
BASFI (0–10)4.8 (2.7–6.7)5.6 (2.9–7.3)0.413.8 (2.0–5.8)2.9 (1.4–5.7)0.57
BASDAI (0–10)6.1 (3.8–7.2)5.7 (4.0–7.6)0.423.9 (1.8–6.5)4.2 (2.9–5.3)0.37
ASDAS‡3.65 (2.81–4.17)3.71 (2.87–4.46)0.972.62 (1.55–3.27)1.98 (1.52–3.39)0.16
ESR (mm/h)14 (6–37)23 (5–40)0.878 (4–27)10 (4–16)0.03
CRP (mg/l)12 (5–32)10 (5–27)0.815 (2–11)5 (4–7)0.10
Patient global VAS (mm)59 (33–82)61 (37–79)0.8531 (20–53)37 (17–59)0.98
Pain VAS (mm)60 (47–73)53 (39–73)0.4032 (21–52)33 (11–56)0.89
Fatigue VAS (mm)58 (40–76)64 (37–80)0.6748 (21–73)50 (23–76)0.92
Physician global VAS (mm)31 (25–63)39 (24–58)0.8924 (12–34)17 (8–30)0.48
SF-36 PCS29 (25–36)28 (23–35)0.2937 (27–43)33 (27–42)0.37
SF-36 MCS43 (34–55)44 (36–54)0.9449 (38–58)49 (32–57)0.37
SF-6D0.55 (0.46–0.65)0.56 (0.51–0.64)0.670.68 (0.55–0.76)0.62 (0.51–0.72)0.54
  • Values are median (IQR) unless otherwise indicated.

  • * Mann–Whitney U test.

  • χ2test/ranked analysis of covariance adjusted for baseline.

  • BASDAI, BASDAI and ASDAS data and ASAS responses were not available for all patients (see details in text).

  • AE, adverse event; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASAS, Assessments of Spondyloarthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; IR, insufficient response; MCS, mental components summary; PCS, physical components summary; SF-36, 36-item Short-Form Health Survey; TNFi, tumour necrosis factor inhibitor; VAS, Visual Analogue Scale.